In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Millennium acquires LeukoSite for $585mm

Executive Summary

Millennium Pharmaceuticals has acquired LeukoSite (cancer, autoimmune, and inflammatory disease therapeutics) for about $585mm. Millennium has issued common stock worth about $33 (0.43 share) for each LeukoSite share; that's a (pr)62% premium to LeukoSite's market average.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies